China's market regulator unconditionally approved during July 13-19, 2026 a new joint venture by Hangyang Group and Shandong Haili Chemical, and also cleared Shanghai Pharma E-Health's acquisition of equity in 18 companies, including Shanghai Pharma Yiyao Pharmacy (Huimin).